[1] Rebecca LS, Kimberly DM, Nikita Sandeep W, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73:17-48. [2] Chen X, Zhang J, Lei X, et al. CD1C is associated with breast cancer prognosis and immune infiltrates[J]. BMC Cancer, 2023, 23:129. doi: 10.1186/s12885-023-10558-2. [3] Shi W, Tang Y, Lu J, et al. MIR210HG promotes breast cancer progression by IGF2BP1 mediated m6A modifica-tion[J]. Cell Biosci, 2022, 12:38. doi: 10.1186/s13578-022-00772-z. [4] Muk T, Brunse A, Henriksen NL, et al. Glucose supply and glycolysis inhibition shape the clinical fate of Staphylococcus epidermidis-infected preterm newborns[J]. JCI Insight, 2022, 7:e157234. doi: 10.1172/jci.insight.157234. [5] Lin Z, Yang Z, Li-Chao P, et al. Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma[J]. World J Gastroenterol, 2022, 28:4600-4619. [6] Lai GH, Wang F, Nie DR, et al. Correlation of glucose metabolism with cancer and intervention with traditional Chinese medicine[J]. Evid Based Complement Alternat Med, 2022, 2022:2192654. doi: 10.1155/2022/2192654. [7] Ajazi A, Choudhary R, Tronci L, et al. CTP sensing and Mec1ATR-Rad53CHK1/CHK2 mediate a two-layered response to inhibition of glutamine metabolism[J]. PLoS Genet, 2022, 18:e101010. doi: 10.1371/journal.pgen.1010101. [8] Jiang H, Wei H, Wang H, et al. Zeb1-induced metabolic reprogramming of glycolysis is essential for macrophage polarization in breast cancer[J]. Cell Death Dis, 2022, 13:206. doi: 10.1038/s41419-022-04632-z. [9] Abenavoli EM, Barbetti M, Linguanti F, et al. Characterization of Mediastinal Bulky Lymphomas with FDG-PET-based radiomics and machine learning techniques[J]. Cancers (Basel), 2023,15:1931. doi: 10.3390/cancers15071931. [10] Zhang D, Tang J, Xu Y, et al. Global crotonylome reveals hypoxia-mediated lamin A crotonylation regulated by HDAC6 in liver cancer[J]. Cell Death Dis, 2022, 13: 717. doi: 10.1038/s41419-022-05165-1. [11] Wang F, Ma S, Chen P, et al. Imaging the metabolic reprograming of fatty acid synthesis pathway enables new diagnostic and therapeutic opportunity for breast cancer[J]. Cancer Cell Int, 2023, 23: 83. doi: 10.1186/s12935-023-02908-8. [12] Oshi M, Roy A, Yan L, et al. Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer[J]. Am J Cancer Res, 2023, 13: 3041-3054. [13] Chen Y, Xu J, Pan W, et al. Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells[J]. Thoracic cancer, 2022, 13: 1961-1973. [14] Park JH, Han HS, Lim SD, et al. Fatty acid synthetase expression in triple-negative breast cancer[J]. J Pathol Transl Med, 2022, 56: 73-80. [15] Xiao Y, Ma D, Yang Y, et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer[J]. Cell Res, 2022, 32: 477-490. [16] Zielke C, Gutierrez Ramirez A, Voss K, et al. Droplet microfluidic technology for the early and label-free isolation of highly-glycolytic, activated T-cells[J]. Micromachines, 2022, 13:1442. doi: 10.3390/mi13091442. [17] Li H, Miao Y, Suo L, et al. CD206 modulates the role of M2 macrophages in the origin of metastatic tumors[J]. J Cancer, 2024, 15: 1462-1486. [18] Zhang G, Zhu X, Yang F, et al. Pseudolycorine chloride ameliorates Th17 cell-mediated central nervous system autoimmunity by restraining myeloid-derived suppressor cell expansion[J]. Pharm Biol, 2022, 60: 899-908. [19] Han B, Zhang H, Tian R, et al. Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling[J]. Theranostics, 2022, 12: 4127-4146. [20] Xue L, Wu M, Li Y, et al. Hexokinase 2 is a pivot for lovastatin-induced glycolysis-to-autophagy reprogramming in triple-negative breast cancer cells[J]. J Cancer, 2022, 13: 3368-3377. [21] Majchrzak-Stiller B, Buchholz M, Peters I, et al. GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-κB pathway in pancreatic cancer cells[J]. J Cell Mol Med, 2023, 27: 2082-2092. [22] Laurence B, Delphine L, Philippe A, et al. Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase Ⅰ/Ⅱ trial[J]. Nat Commun, 2023, 14:7018. doi: 10.1038/s41467-023-42744-y. |